Teva is returning the rights to commercialize the small molecule gene-related peptide CGRP antagonist HTL0022562 as part of its streamlining plan.



Latest News

Daily Mail: Maryland county settles lawsuit with transgender teen

Daily Mail: 10 Things to Know for Tuesday - 19 June 2018

Daily Mail: Robert F. Kennedy bumps into Michelle Obama on a hike in the Santa Monica mountains 

Daily Mail: N. Korea's Kim 'planning China visit': report

Daily Mail: Ravers are robbed of their wallets, passports and bags during late-night rave at abandoned building

Daily Mail: Katie Price branded 'irresponsible' after showing a car ride with son Jett WITHOUT a seat belt

Daily Mail: notebook: Vikings to honor late coach Green

Daily Mail: Stocks extend slide, yen up as Sino-US trade dispute...

CNBC: Political risks are 'certainly rising' for the euro: Strategist

CNBC: Ex-CIA employee charged with leaking classified data, child porn offenses

Reuters: PRESS DIGEST- Financial Times - June 19

Jpost: Cutting off Iran’s 'road to the sea' in Syria

WashingtonPost: Barry Trotz’s resignation shouldn’t take shine off Stanley Cup triumph

NewYorkTimes: Extreme Heat Rolls Across U.S., but Relief Is Coming

FOX: Pentagon suspends military exercises on Korean peninsula

FOX: Republicans demand names of anti-Trump FBI employees from bombshell IG report

CNN: The 2018 MTV Movie & TV Awards: Highlights

USA Today: Nielsen rejects criticism on family separation

USA Today: How we handle bad-check cases

USA Today: Nationals get RHP Kelvin Herrera from Royals for 3 players

USA Today: Every James Bond film ranked from worst to best

Daily Mail: Video: Back in Black! Kourtney Kardashian wears tight black shorts

Daily Mail: Young father takes a selfie after plunging 15 metres down a dark mine shaft

8 Related Articles from 2018-02-26